The consolidated net sales reported in Q1FY21 came in at Rs 277.47 crore, which   declined by 66.62 per cent YoY from Rs 831.19 crore in Q1FY20. 

Lately, pharma funds have performed spectacularly giving double-digit returns. Here are the top pharma funds that you can consider investing in.

The market opened in red on August 7, 2020. 

The market opened in red on August 7, 2020, overall volumes in futures & options currently stand at 6,09,80,826 crore contracts with a turnover of Rs. 39,88,372.83 crore.

The market opened in red on August 7, 2020, overall volumes in futures & options currently stand at 6,09,80,826 crore contracts with a turnover of Rs. 39,88,372.83 crore.

Lupin Limited announced that the company’s US-based wholly-owned subsidiary Lupin Pharmaceuticals Inc. has entered into an agreement with ForDoz Pharma Corp (ForDoz).

Global pharma major, Glenmark Pharmaceuticals announced on Thursday that it is launching a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. Glenmark Pharmaceuticals was the first company in the country to have received the regulator’s approval for 400 mg dosage form.

The consolidated net sales reported in Q1FY21 came in at Rs 3,527.86 crore, which declined by 9.02 per cent YoY from Rs 3,877.69 crore in Q1FY20. 

As markets witnessed a strong rebound from lower levels and closed above the 11,200 level, the 'buy on dip' strategy worked quite well on Thursday's session.  On Friday, cues from Asian peers are mostly negative and hence, today's session is likely to begin on a cautious note.

As the daily bars are making higher highs and higher lows, it is better to continue the long positions with a trailing stop-loss. Stocks in news: Prince Pipes and Fittings, SML ISUZU, Jubilant FoodWorks, TCS, Lupin, Wipro.